Published in Psychiatry (Edgmont) on March 01, 2009
Identification of Adverse Drug Events from Free Text Electronic Patient Records and Information in a Large Mental Health Case Register. PLoS One (2015) 0.98
A group ICA based framework for evaluating resting fMRI markers when disease categories are unclear: application to schizophrenia, bipolar, and schizoaffective disorders. Neuroimage (2015) 0.83
A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder. Ther Clin Risk Manag (2016) 0.76
Psychiatric comorbidities and schizophrenia. Schizophr Bull (2008) 2.69
Antipsychotic polypharmacy, part 1: Shotgun approach or targeted cotreatment? J Clin Psychiatry (2008) 1.16
Major psychoses with mixed psychotic and mood symptoms: are mixed psychoses associated with different neurobiological markers? Acta Psychiatr Scand (2008) 1.12
Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry (2011) 3.33
Randomized, double-blind, placebo-controlled study of paliperidone extended-release and quetiapine in inpatients with recently exacerbated schizophrenia. Am J Psychiatry (2009) 3.26
Can acute overdose of metformin lead to lactic acidosis? Am J Emerg Med (2010) 2.44
Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. J Clin Psychiatry (2015) 2.03
Treatment of depression: antidepressant monotherapy and combination therapy. Psychiatry (Edgmont) (2007) 1.50
Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled study. Am J Psychiatry (2011) 1.40
What is causing the reduced drug-placebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull (2008) 1.38
Transcriptome transfer produces a predictable cellular phenotype. Proc Natl Acad Sci U S A (2009) 1.37
Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry (2013) 1.27
Real-World Data on SSRI Antidepressant Side Effects. Psychiatry (Edgmont) (2009) 1.21
Insulin causes hyperthermia by direct inhibition of warm-sensitive neurons. Diabetes (2009) 1.16
Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol (2008) 1.12
Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial. Schizophr Res (2013) 1.09
Recent changes in prescriptions for antipsychotics in children and adolescents. Psychiatry (Edgmont) (2006) 1.08
Pharmacogenetics and schizophrenia. Clin Lab Med (2010) 1.06
Multiple pain complaints in patients with major depressive disorder. Psychosom Med (2008) 1.04
A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry (2004) 1.04
Reduction in psychotic symptoms as a predictor of patient satisfaction with antipsychotic medication in schizophrenia: data from a randomized double-blind trial. BMC Psychiatry (2006) 1.04
Prevalence and association of somatic symptoms in patients with Major Depressive Disorder. J Affect Disord (2008) 1.02
Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry (2012) 0.98
Daytrana: the first year. Psychiatry (Edgmont) (2007) 0.97
Immuno-inflammatory, oxidative and nitrosative stress, and neuroprogressive pathways in the etiology, course and treatment of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.96
Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J Psychopharmacol (2009) 0.95
Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry (2005) 0.94
Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients. Schizophr Res (2010) 0.92
A systematic, quantitative review of blood autoantibodies in schizophrenia. Schizophr Res (2013) 0.91
Defining "good" and "poor" outcomes in patients with schizophrenia or schizoaffective disorder: a multidimensional data-driven approach. Psychiatry Res (2009) 0.91
Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol (2003) 0.91
Carbamazepine and valproate for the treatment of bipolar disorder: a review of the literature. J Affect Disord (2006) 0.91
Lipidomics reveals early metabolic changes in subjects with schizophrenia: effects of atypical antipsychotics. PLoS One (2013) 0.91
Massive pneumoperitoneum. West J Emerg Med (2010) 0.90
Prenatal inflammation and neurodevelopment in schizophrenia: a review of human studies. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.90
BacMam recombinant baculoviruses in G protein-coupled receptor drug discovery. Receptors Channels (2004) 0.89
Symptoms of anxiety in depression: assessment of item performance of the Hamilton Anxiety Rating Scale in patients with depression. Depress Anxiety (2008) 0.88
Insight into illness and attitudes toward medications among inpatients with schizophrenia. Psychiatr Serv (2002) 0.86
Varying uses of anticonvulsant medications. Psychiatry (Edgmont) (2008) 0.85
Use of Antipsychotics Pre- and Post-Dissemination of CATIE Data. Psychiatry (Edgmont) (2007) 0.83
Quantitative biology of single neurons. J R Soc Interface (2012) 0.83
Seasonality and the changing adult/child prescription ratios in ADHD therapy. Psychiatry (Edgmont) (2008) 0.82
Antidepressants in bipolar disorder. Psychiatry (Edgmont) (2007) 0.82
Short-acting versus Long-acting Medications for the Treatment of ADHD. Psychiatry (Edgmont) (2008) 0.82
Strattera: ups, downs, and emerging uses. Psychiatry (Edgmont) (2007) 0.82
Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses. Brain Behav Immun (2012) 0.81
Long-term safety and tolerability of iloperidone: results from a 25-week, open-label extension trial. CNS Spectr (2013) 0.81
A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry (2004) 0.81
Use of benzodiazepines in the treatment of anxiety. Psychiatry (Edgmont) (2008) 0.80
Generic penetration in the retail antidepressant market. Psychiatry (Edgmont) (2010) 0.80
Use of antidepressants: expansion beyond depression and anxiety. Psychiatry (Edgmont) (2007) 0.80
Generic penetration in the retail atypical antipsychotic market. Psychiatry (Edgmont) (2010) 0.80
Treatment of autistic children. Psychiatry (Edgmont) (2008) 0.80
Real-World Data on: Attention Deficit Hyperactivity Disorder Medication Side Effects. Psychiatry (Edgmont) (2010) 0.80
An open-label extension trial of risperidone monotherapy in the treatment of bipolar I disorder. Int Clin Psychopharmacol (2006) 0.79
Generic Penetration of the SSRI Market. Psychiatry (Edgmont) (2008) 0.79
A review of new atypical antipsychotic launches in the United States. Psychiatry (Edgmont) (2010) 0.78
Current status of hypnotic prescribing habits in the United States. Psychiatry (Edgmont) (2007) 0.78
Frequency of schizoaffective disorder in an International patient population with psychotic disorders using the Mini-International Neuropsychiatric Interview. Schizophr Res (2010) 0.78
Antipsychotic use varies by patient age. Psychiatry (Edgmont) (2007) 0.78
Current Management of Schizophrenia: Antipsychotic Monotherapy versus Combination Therapy. Psychiatry (Edgmont) (2008) 0.78
High-dose oral ziprasidone versus conventional dosing in schizophrenia patients with residual symptoms: the ZEBRAS study. J Clin Psychopharmacol (2013) 0.78
Trends in CNS prescribing following the economic slowdown. Psychiatry (Edgmont) (2009) 0.77
Polypharmacy of schizophrenia. Psychiatry (Edgmont) (2010) 0.77
Discovery of novel 8-azoniabicyclo[3.2.1]octane carbamates as muscarinic acetylcholine receptor antagonists. Bioorg Med Chem Lett (2007) 0.77
Average Out-of-Pocket Expenses Across Different Drug Categories and Commercial Third-Party Payers. Psychiatry (Edgmont) (2010) 0.77
Pharmacogenetics of antipsychotic adverse effects: Case studies and a literature review for clinicians. Neuropsychiatr Dis Treat (2007) 0.77
Why the Hamilton Depression Rating Scale endures. Am J Psychiatry (2005) 0.76
Emsam: the first year. Psychiatry (Edgmont) (2007) 0.76
Treatment of bipolar disorder. Psychiatry (Edgmont) (2009) 0.76
Antidepressant prescribing by specialty and treatment of premenstrual dysphoric disorder. Psychiatry (Edgmont) (2008) 0.76
Alzheimer's therapies. Psychiatry (Edgmont) (2007) 0.75
Quantitative levels of aripiprazole parent drug and metabolites in urine. Psychopharmacology (Berl) (2014) 0.75
Safety of carbamazepine extended-release capsules used in combination with other psychotropic medications for the treatment of bipolar I disorder. Psychiatry (Edgmont) (2008) 0.75
Treatment of fibromyalgia. Psychiatry (Edgmont) (2008) 0.75
Efficacy and Safety of Once- versus Twice-Daily Carbamazepine Extended-Release Capsules for the Treatment of Manic Symptoms in Patients with Bipolar I Disorder. Psychiatry (Edgmont) (2008) 0.75
Treatment of migraine and the role of psychiatric medications. Psychiatry (Edgmont) (2008) 0.75
Analysis of Classes Used in the Treatment of Depression by Physician-reported Severity. Psychiatry (Edgmont) (2010) 0.75
Treatment of fibromyalgia. Psychiatry (Edgmont) (2010) 0.75
An analysis of the intended use of atypical antipsychotics in dementia. Psychiatry (Edgmont) (2010) 0.75
Use of atypical antipsychotics in the elderly. Psychiatry (Edgmont) (2008) 0.75
Update on trends in antidepressant use: Upswing in 2006 Following Period of Decline. Psychiatry (Edgmont) (2006) 0.75
Real-world Data on Atypical Antipsychotic Medication Side Effects. Psychiatry (Edgmont) (2010) 0.75
Prescribing for buprenorphine in the treatment of opioid addiction. Psychiatry (Edgmont) (2007) 0.75
Assessing onset of treatment benefit in depression and anxiety: conceptual considerations. J Clin Psychiatry (2009) 0.75
Violence and schizophrenia. J Med Assoc Ga (2013) 0.75
What Treatments are Prescribed for Posttraumatic Stress Disorder? Psychiatry (Edgmont) (2007) 0.75
Generic Conversion of the SSRI Market and the Impact on Branded Products. Psychiatry (Edgmont) (2006) 0.75
Open-label study of the effect of combination quetiapine/lithium therapy on lithium pharmacokinetics and tolerability. Clin Ther (2002) 0.75
Schizophrenia: from brain morphology to psychopathology. Curr Psychiatry Rep (2007) 0.75
Using new antipsychotics in your clinical practice. J Clin Psychiatry (2010) 0.75
New name, school still addressing physician shortages in Georgia. J Med Assoc Ga (2011) 0.75
Combination Antipsychotic Therapies: An Analysis From a Longitudinal Pragmatic Trial. J Clin Psychopharmacol (2017) 0.75
Gender related differences in clinical characteristics and hospital based resource utilization among older adults with schizophrenia. Int J Geriatr Psychiatry (2002) 0.75
Psychiatrists are Significant Prescribers of Sleep Aids, but their Reasons are Different than Primary Care. Psychiatry (Edgmont) (2006) 0.75
Switching from other agents to extended-release carbamazepine in acute mania. Psychopharmacol Bull (2008) 0.75
An analysis of the psychiatric pipeline. Psychiatry (Edgmont) (2010) 0.75